NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-08-31
Reading LH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Intact: The reason to own it still holds.
Labcorp grows revenue about 6% a year. It raised 2026 revenue guidance to $14.72 billion. Profit per share is expected near $18. Free cash flow is strong at about $1.3 billion. New AI tools and cancer trial partnerships support growth.
Revenue growth could slow below 6%. Profit per share might miss $18. Cash flow could weaken. Management changes and debt raise risks.
The price is about 14% below our fair value near $328. Analysts expect 6% revenue growth. We agree with these views.
Breaks if: Adjusted EPS falls below $17.0 in FY26
Breaks if: Free cash flow falls below $1.1 billion in FY26
Breaks if: No revenue growth from AI or oncology partnerships in 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent earnings and revenue growth. The current thesis state is intact, supported by recent strong financial performance and management's commitment to increasing guidance.
The market appears to have priced in a neutral valuation, with expectations closely aligned to recent performance. Labcorp is viewed as cheap compared to its peers, indicating that there may be limited downside risk.
Fundamentals are likely to show continued growth, as management is on track to meet its adjusted EPS and revenue guidance for 2026. However, there is a moderate risk due to the potential for economic downturns affecting the healthcare sector.
The thesis hinges on management's ability to maintain or raise guidance without cutting expectations, as well as the overall health of the labor market and its impact on cyclical healthcare stocks. Additionally, performance from sector leaders could influence Labcorp's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company beat earnings expectations in Q2. It raised its full-year revenue outlook after this strong performance. Analysts also revised earnings estimates upwards, indicating higher expectations. There are no new threats to the thesis at this time.
as of 2026-08-31
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Revenue falls below $13.9 billion in FY26
Overall, Labcorp's strong recent performance and management execution support a positive long-term view. Not investment advice.
